Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetic Retinopathy | 194 | 2024 | 1275 | 20.620 |
Why?
|
Macular Edema | 64 | 2023 | 374 | 8.190 |
Why?
|
Retinal Vessels | 50 | 2023 | 851 | 5.040 |
Why?
|
Retina | 69 | 2024 | 2652 | 4.430 |
Why?
|
Photography | 26 | 2023 | 531 | 4.320 |
Why?
|
Diagnostic Techniques, Ophthalmological | 15 | 2019 | 251 | 3.140 |
Why?
|
Visual Acuity | 62 | 2021 | 2662 | 3.130 |
Why?
|
Fluorescein Angiography | 33 | 2023 | 1051 | 2.240 |
Why?
|
Diabetes Mellitus, Type 1 | 65 | 2024 | 3439 | 2.140 |
Why?
|
Ophthalmoscopy | 12 | 2018 | 171 | 2.090 |
Why?
|
Retinal Diseases | 16 | 2023 | 704 | 2.080 |
Why?
|
Endothelial Growth Factors | 29 | 2002 | 673 | 2.020 |
Why?
|
Lymphokines | 29 | 2002 | 927 | 1.940 |
Why?
|
Telemedicine | 19 | 2024 | 3027 | 1.780 |
Why?
|
Laser Coagulation | 27 | 2014 | 330 | 1.720 |
Why?
|
Protein Kinase C | 20 | 2013 | 1202 | 1.650 |
Why?
|
Vitreous Body | 29 | 2024 | 399 | 1.630 |
Why?
|
Diabetes Mellitus | 27 | 2024 | 5835 | 1.580 |
Why?
|
Tomography, Optical Coherence | 49 | 2024 | 2907 | 1.550 |
Why?
|
Maleimides | 12 | 2013 | 113 | 1.540 |
Why?
|
Ophthalmology | 11 | 2023 | 550 | 1.470 |
Why?
|
Angiogenesis Inhibitors | 19 | 2021 | 2047 | 1.450 |
Why?
|
Retinal Neovascularization | 13 | 2015 | 288 | 1.440 |
Why?
|
Mydriatics | 7 | 2022 | 67 | 1.400 |
Why?
|
Triamcinolone Acetonide | 11 | 2013 | 100 | 1.270 |
Why?
|
Vitrectomy | 14 | 2015 | 391 | 1.160 |
Why?
|
Receptors, Growth Factor | 11 | 2002 | 326 | 1.160 |
Why?
|
Telepathology | 6 | 2016 | 77 | 1.130 |
Why?
|
Vision Disorders | 11 | 2014 | 1088 | 1.020 |
Why?
|
Indoles | 13 | 2013 | 1833 | 0.990 |
Why?
|
Pupil | 6 | 2016 | 146 | 0.960 |
Why?
|
Fenofibrate | 1 | 2024 | 87 | 0.910 |
Why?
|
Enzyme Inhibitors | 15 | 2013 | 3710 | 0.900 |
Why?
|
Vascular Endothelial Growth Factor A | 50 | 2022 | 3486 | 0.900 |
Why?
|
Phacoemulsification | 2 | 2015 | 149 | 0.860 |
Why?
|
Lens Implantation, Intraocular | 2 | 2015 | 190 | 0.850 |
Why?
|
Disease Progression | 24 | 2024 | 13484 | 0.840 |
Why?
|
Retinal Hemorrhage | 3 | 2020 | 95 | 0.830 |
Why?
|
Macula Lutea | 5 | 2019 | 169 | 0.810 |
Why?
|
Choroidal Neovascularization | 3 | 2012 | 363 | 0.780 |
Why?
|
Diagnostic Imaging | 6 | 2015 | 3541 | 0.740 |
Why?
|
Receptor Protein-Tyrosine Kinases | 11 | 2002 | 1624 | 0.730 |
Why?
|
Fundus Oculi | 19 | 2020 | 548 | 0.710 |
Why?
|
Eye | 6 | 2024 | 710 | 0.700 |
Why?
|
Endocrinology | 2 | 2020 | 442 | 0.690 |
Why?
|
Diabetes Mellitus, Type 2 | 38 | 2022 | 12127 | 0.680 |
Why?
|
Hypolipidemic Agents | 1 | 2024 | 609 | 0.680 |
Why?
|
Vascular Endothelial Growth Factors | 29 | 2002 | 748 | 0.650 |
Why?
|
Glucocorticoids | 10 | 2013 | 2163 | 0.590 |
Why?
|
Injections | 15 | 2011 | 829 | 0.590 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 15 | 2019 | 664 | 0.550 |
Why?
|
Diabetes Complications | 9 | 2021 | 1317 | 0.540 |
Why?
|
Endothelium, Vascular | 18 | 2011 | 4430 | 0.530 |
Why?
|
Humans | 231 | 2024 | 760437 | 0.530 |
Why?
|
Light Coagulation | 9 | 2015 | 71 | 0.520 |
Why?
|
Eye Proteins | 8 | 2022 | 633 | 0.520 |
Why?
|
Middle Aged | 113 | 2024 | 220382 | 0.510 |
Why?
|
Image Processing, Computer-Assisted | 9 | 2015 | 8967 | 0.510 |
Why?
|
Severity of Illness Index | 19 | 2024 | 15820 | 0.470 |
Why?
|
Capillary Permeability | 10 | 2016 | 773 | 0.470 |
Why?
|
Male | 127 | 2024 | 360035 | 0.460 |
Why?
|
Cattle | 25 | 2015 | 3849 | 0.450 |
Why?
|
Glaucoma | 8 | 2016 | 1183 | 0.450 |
Why?
|
Physical Examination | 4 | 2015 | 1254 | 0.440 |
Why?
|
Mitogen-Activated Protein Kinases | 3 | 2006 | 1246 | 0.440 |
Why?
|
Vision Screening | 4 | 2018 | 72 | 0.420 |
Why?
|
Female | 118 | 2024 | 391875 | 0.420 |
Why?
|
Hyperlipidemias | 1 | 2017 | 771 | 0.410 |
Why?
|
Aged | 73 | 2024 | 168840 | 0.410 |
Why?
|
Hepatocyte Growth Factor | 2 | 2006 | 270 | 0.400 |
Why?
|
Diagnosis, Computer-Assisted | 3 | 2016 | 708 | 0.400 |
Why?
|
Adult | 81 | 2024 | 220781 | 0.390 |
Why?
|
Office Visits | 1 | 2015 | 594 | 0.370 |
Why?
|
Blood Glucose | 13 | 2024 | 6380 | 0.360 |
Why?
|
Prospective Studies | 24 | 2024 | 54339 | 0.350 |
Why?
|
Insulin | 8 | 2016 | 6591 | 0.340 |
Why?
|
Aqueous Humor | 2 | 2024 | 153 | 0.340 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 3 | 2019 | 544 | 0.340 |
Why?
|
Blood-Retinal Barrier | 3 | 2006 | 62 | 0.330 |
Why?
|
Pigment Epithelium of Eye | 5 | 2007 | 209 | 0.330 |
Why?
|
Hypoglycemic Agents | 6 | 2016 | 3076 | 0.310 |
Why?
|
Plasma Kallikrein | 2 | 2019 | 21 | 0.300 |
Why?
|
PPAR gamma | 2 | 2008 | 483 | 0.300 |
Why?
|
Thiazolidinediones | 2 | 2008 | 461 | 0.300 |
Why?
|
Neovascularization, Pathologic | 12 | 2006 | 2642 | 0.290 |
Why?
|
Polypharmacy | 1 | 2010 | 305 | 0.290 |
Why?
|
Myopia, Degenerative | 1 | 2007 | 15 | 0.290 |
Why?
|
Growth Substances | 3 | 2000 | 768 | 0.290 |
Why?
|
Phosphatidylinositol 3-Kinases | 5 | 2006 | 2860 | 0.290 |
Why?
|
Retinol-Binding Proteins | 3 | 2024 | 67 | 0.280 |
Why?
|
Antibodies, Monoclonal | 8 | 2011 | 9176 | 0.270 |
Why?
|
Cross-Sectional Studies | 17 | 2024 | 26063 | 0.270 |
Why?
|
Retrospective Studies | 22 | 2023 | 80430 | 0.260 |
Why?
|
Follow-Up Studies | 28 | 2020 | 39078 | 0.260 |
Why?
|
RNA, Messenger | 23 | 2009 | 12785 | 0.250 |
Why?
|
Retinal Detachment | 6 | 2015 | 428 | 0.250 |
Why?
|
Intravitreal Injections | 9 | 2019 | 385 | 0.250 |
Why?
|
Aged, 80 and over | 30 | 2015 | 58859 | 0.240 |
Why?
|
Erythropoietin | 2 | 2008 | 719 | 0.240 |
Why?
|
Diabetic Angiopathies | 4 | 2007 | 804 | 0.240 |
Why?
|
Adenosine | 3 | 1998 | 804 | 0.230 |
Why?
|
Cells, Cultured | 26 | 2015 | 18955 | 0.230 |
Why?
|
Isoenzymes | 5 | 2002 | 1688 | 0.230 |
Why?
|
Capillaries | 6 | 2021 | 755 | 0.220 |
Why?
|
Steroids | 1 | 2009 | 928 | 0.220 |
Why?
|
Diabetic Nephropathies | 7 | 2011 | 973 | 0.220 |
Why?
|
Endophthalmitis | 3 | 2007 | 260 | 0.220 |
Why?
|
Cell Division | 8 | 2002 | 4461 | 0.210 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2016 | 3346 | 0.210 |
Why?
|
Myopia | 3 | 2020 | 251 | 0.210 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 4 | 2024 | 3800 | 0.210 |
Why?
|
Growth Inhibitors | 1 | 2004 | 378 | 0.210 |
Why?
|
Sp1 Transcription Factor | 2 | 2004 | 140 | 0.200 |
Why?
|
Optic Nerve Neoplasms | 1 | 2002 | 45 | 0.200 |
Why?
|
Diabetes Mellitus, Experimental | 4 | 2015 | 1115 | 0.200 |
Why?
|
Signal Processing, Computer-Assisted | 5 | 2012 | 1496 | 0.200 |
Why?
|
Hemangioblastoma | 1 | 2002 | 63 | 0.200 |
Why?
|
Kallikrein-Kinin System | 2 | 2015 | 9 | 0.200 |
Why?
|
Sensitivity and Specificity | 8 | 2019 | 14661 | 0.200 |
Why?
|
Mass Screening | 5 | 2015 | 5424 | 0.200 |
Why?
|
Refraction, Ocular | 3 | 2014 | 183 | 0.200 |
Why?
|
Retinal Vein Occlusion | 2 | 2014 | 149 | 0.190 |
Why?
|
Cataract | 6 | 2015 | 831 | 0.190 |
Why?
|
Glaucoma, Neovascular | 2 | 2012 | 36 | 0.190 |
Why?
|
Reproducibility of Results | 17 | 2020 | 20078 | 0.190 |
Why?
|
von Hippel-Lindau Disease | 1 | 2002 | 151 | 0.190 |
Why?
|
Young Adult | 15 | 2019 | 59068 | 0.190 |
Why?
|
Vision Tests | 6 | 2011 | 161 | 0.190 |
Why?
|
Retinal Neurons | 1 | 2021 | 66 | 0.180 |
Why?
|
Hyperopia | 1 | 2020 | 41 | 0.180 |
Why?
|
Eye Injuries, Penetrating | 2 | 1992 | 124 | 0.180 |
Why?
|
Ocular Hypertension | 2 | 2011 | 208 | 0.180 |
Why?
|
Animals | 61 | 2019 | 168253 | 0.180 |
Why?
|
Retreatment | 6 | 2018 | 598 | 0.180 |
Why?
|
Cohort Studies | 11 | 2023 | 41366 | 0.180 |
Why?
|
Gene Expression | 7 | 2002 | 7582 | 0.170 |
Why?
|
Proto-Oncogene Proteins | 4 | 2001 | 4509 | 0.170 |
Why?
|
Referral and Consultation | 4 | 2018 | 3596 | 0.170 |
Why?
|
Intraocular Pressure | 4 | 2014 | 1291 | 0.170 |
Why?
|
Gene Expression Regulation | 9 | 2015 | 11900 | 0.170 |
Why?
|
Epoprostenol | 1 | 2000 | 246 | 0.160 |
Why?
|
Receptors, Purinergic P1 | 2 | 1996 | 108 | 0.160 |
Why?
|
Administration, Oral | 8 | 2013 | 4010 | 0.160 |
Why?
|
Vitreous Hemorrhage | 2 | 2015 | 48 | 0.160 |
Why?
|
Treatment Outcome | 24 | 2019 | 64591 | 0.160 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 2 | 2007 | 476 | 0.160 |
Why?
|
Purinergic P1 Receptor Agonists | 1 | 1998 | 39 | 0.160 |
Why?
|
Choroid | 1 | 2020 | 352 | 0.150 |
Why?
|
Dose-Response Relationship, Drug | 9 | 2014 | 10759 | 0.150 |
Why?
|
Optic Disk | 2 | 2002 | 421 | 0.150 |
Why?
|
Risk Factors | 24 | 2023 | 74055 | 0.150 |
Why?
|
Rats | 20 | 2016 | 23712 | 0.150 |
Why?
|
Double-Blind Method | 14 | 2015 | 12320 | 0.150 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1999 | 489 | 0.150 |
Why?
|
Combined Modality Therapy | 10 | 2013 | 8522 | 0.150 |
Why?
|
Blood Proteins | 4 | 2008 | 1174 | 0.140 |
Why?
|
Adolescent | 27 | 2019 | 88196 | 0.140 |
Why?
|
National Eye Institute (U.S.) | 1 | 2016 | 4 | 0.140 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 1999 | 591 | 0.140 |
Why?
|
Blotting, Western | 7 | 2016 | 5031 | 0.140 |
Why?
|
Blindness | 6 | 2001 | 584 | 0.140 |
Why?
|
Monosaccharide Transport Proteins | 1 | 1998 | 436 | 0.140 |
Why?
|
Ischemia | 4 | 2002 | 1876 | 0.140 |
Why?
|
Clinical Trials as Topic | 6 | 2016 | 7996 | 0.140 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 4 | 2011 | 557 | 0.140 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 3 | 2010 | 1517 | 0.130 |
Why?
|
Point-of-Care Systems | 2 | 2015 | 1212 | 0.130 |
Why?
|
Retinopathy of Prematurity | 2 | 2002 | 439 | 0.130 |
Why?
|
Tropicamide | 2 | 2013 | 22 | 0.130 |
Why?
|
Zinc Fingers | 1 | 1998 | 572 | 0.130 |
Why?
|
Antimicrobial Cationic Peptides | 3 | 2007 | 353 | 0.130 |
Why?
|
Cataract Extraction | 5 | 2015 | 466 | 0.130 |
Why?
|
Pyrroles | 1 | 2002 | 1126 | 0.130 |
Why?
|
Patient Compliance | 1 | 2006 | 2689 | 0.130 |
Why?
|
Lightning Injuries | 1 | 1995 | 2 | 0.130 |
Why?
|
Cardiovascular System | 2 | 2021 | 835 | 0.130 |
Why?
|
Kinins | 1 | 2015 | 14 | 0.130 |
Why?
|
Blotting, Northern | 6 | 1997 | 1545 | 0.130 |
Why?
|
Pilot Projects | 5 | 2023 | 8611 | 0.130 |
Why?
|
Remote Consultation | 1 | 2008 | 237 | 0.130 |
Why?
|
Observer Variation | 4 | 2012 | 2604 | 0.130 |
Why?
|
Pericytes | 3 | 2009 | 293 | 0.120 |
Why?
|
Cell Hypoxia | 5 | 1998 | 656 | 0.120 |
Why?
|
Phenylephrine | 2 | 2013 | 293 | 0.120 |
Why?
|
Recombinant Fusion Proteins | 4 | 2018 | 3734 | 0.120 |
Why?
|
Sulfonamides | 2 | 2010 | 1973 | 0.120 |
Why?
|
Time Factors | 19 | 2019 | 39947 | 0.120 |
Why?
|
Delivery of Health Care | 3 | 2010 | 5332 | 0.120 |
Why?
|
Pseudophakia | 1 | 2014 | 60 | 0.120 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2000 | 710 | 0.110 |
Why?
|
Cell Movement | 3 | 2019 | 5198 | 0.110 |
Why?
|
Lasers, Dye | 1 | 2013 | 28 | 0.110 |
Why?
|
Kallikreins | 1 | 2015 | 220 | 0.110 |
Why?
|
Apoptosis | 4 | 2016 | 9468 | 0.110 |
Why?
|
Central Serous Chorioretinopathy | 1 | 2014 | 27 | 0.110 |
Why?
|
Muscle, Smooth, Vascular | 3 | 1995 | 1492 | 0.110 |
Why?
|
Computer Systems | 1 | 2015 | 471 | 0.110 |
Why?
|
Hemodynamics | 5 | 2015 | 4167 | 0.100 |
Why?
|
Practice Guidelines as Topic | 5 | 2018 | 7380 | 0.100 |
Why?
|
Sunlight | 1 | 1994 | 337 | 0.100 |
Why?
|
Eye Injuries | 1 | 1995 | 227 | 0.100 |
Why?
|
Keratoplasty, Penetrating | 1 | 1993 | 144 | 0.100 |
Why?
|
Automation | 1 | 2015 | 587 | 0.100 |
Why?
|
Epiretinal Membrane | 2 | 2010 | 73 | 0.100 |
Why?
|
Glucose | 4 | 2009 | 4342 | 0.100 |
Why?
|
Preservatives, Pharmaceutical | 2 | 2009 | 34 | 0.100 |
Why?
|
Protein Kinase Inhibitors | 1 | 2008 | 5662 | 0.100 |
Why?
|
Administration, Topical | 2 | 2008 | 703 | 0.100 |
Why?
|
Proteomics | 4 | 2015 | 3818 | 0.100 |
Why?
|
Fovea Centralis | 2 | 2015 | 126 | 0.100 |
Why?
|
Ophthalmologic Surgical Procedures | 1 | 2015 | 356 | 0.100 |
Why?
|
Signal Transduction | 11 | 2019 | 23397 | 0.100 |
Why?
|
Membrane Glycoproteins | 1 | 2002 | 3701 | 0.100 |
Why?
|
Depth Perception | 1 | 2012 | 94 | 0.100 |
Why?
|
Porphyrins | 1 | 2014 | 352 | 0.100 |
Why?
|
Papilledema | 3 | 2008 | 130 | 0.100 |
Why?
|
ROC Curve | 2 | 2017 | 3571 | 0.090 |
Why?
|
Adenomatous Polyposis Coli | 1 | 1993 | 218 | 0.090 |
Why?
|
Blood Pressure | 9 | 2020 | 8479 | 0.090 |
Why?
|
Societies, Medical | 2 | 2018 | 3904 | 0.090 |
Why?
|
Drug Combinations | 3 | 2013 | 2043 | 0.090 |
Why?
|
Lebanon | 1 | 2011 | 245 | 0.090 |
Why?
|
Self Care | 1 | 2015 | 794 | 0.090 |
Why?
|
Trabecular Meshwork | 1 | 2010 | 101 | 0.090 |
Why?
|
Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2009 | 120 | 0.080 |
Why?
|
HLA-DR Antigens | 3 | 2010 | 631 | 0.080 |
Why?
|
Phosphorylation | 7 | 2007 | 8311 | 0.080 |
Why?
|
Photosensitizing Agents | 1 | 2014 | 623 | 0.080 |
Why?
|
Regional Blood Flow | 5 | 2006 | 1487 | 0.080 |
Why?
|
Protein Kinase C-delta | 1 | 2009 | 114 | 0.080 |
Why?
|
Artificial Intelligence | 2 | 2023 | 2568 | 0.080 |
Why?
|
Specialization | 2 | 2012 | 778 | 0.080 |
Why?
|
Quality Assurance, Health Care | 3 | 2016 | 2167 | 0.080 |
Why?
|
Base Sequence | 9 | 2000 | 12449 | 0.080 |
Why?
|
DNA-Binding Proteins | 3 | 2004 | 9598 | 0.080 |
Why?
|
Incidence | 6 | 2023 | 21322 | 0.080 |
Why?
|
Deoxyglucose | 2 | 2019 | 333 | 0.080 |
Why?
|
Macular Degeneration | 2 | 2012 | 1005 | 0.080 |
Why?
|
Primary Health Care | 1 | 2005 | 4674 | 0.080 |
Why?
|
United States Food and Drug Administration | 1 | 2016 | 1663 | 0.080 |
Why?
|
Cost-Benefit Analysis | 3 | 2016 | 5491 | 0.070 |
Why?
|
Eye Diseases | 4 | 2004 | 655 | 0.070 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2010 | 321 | 0.070 |
Why?
|
Glypicans | 1 | 2007 | 33 | 0.070 |
Why?
|
Oxygen | 2 | 1996 | 4222 | 0.070 |
Why?
|
Age of Onset | 2 | 2010 | 3302 | 0.070 |
Why?
|
Lasers, Solid-State | 1 | 2010 | 175 | 0.070 |
Why?
|
Cardiovascular Diseases | 3 | 2023 | 15476 | 0.070 |
Why?
|
Lasers, Gas | 1 | 2009 | 101 | 0.070 |
Why?
|
Disease Management | 1 | 2018 | 2501 | 0.070 |
Why?
|
Photochemotherapy | 1 | 2014 | 823 | 0.070 |
Why?
|
Rats, Sprague-Dawley | 7 | 2016 | 8163 | 0.070 |
Why?
|
Lens, Crystalline | 3 | 2011 | 389 | 0.070 |
Why?
|
Infant, Premature, Diseases | 1 | 1993 | 710 | 0.070 |
Why?
|
Hypoglycemia | 1 | 1994 | 884 | 0.070 |
Why?
|
Acute-Phase Proteins | 1 | 1988 | 250 | 0.070 |
Why?
|
HLA-D Antigens | 1 | 1986 | 134 | 0.070 |
Why?
|
Cognition | 2 | 2021 | 6973 | 0.070 |
Why?
|
Fluorophotometry | 1 | 2006 | 40 | 0.070 |
Why?
|
Antihypertensive Agents | 2 | 2010 | 2018 | 0.070 |
Why?
|
Choroid Diseases | 1 | 2007 | 63 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2021 | 10180 | 0.070 |
Why?
|
Carbonic Anhydrase Inhibitors | 1 | 2007 | 91 | 0.070 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 1 | 2009 | 431 | 0.070 |
Why?
|
Carbonic Anhydrases | 1 | 2007 | 108 | 0.070 |
Why?
|
Kinetics | 4 | 1999 | 6377 | 0.070 |
Why?
|
Enzyme Activation | 4 | 2006 | 3592 | 0.070 |
Why?
|
Stress, Mechanical | 2 | 2001 | 1674 | 0.070 |
Why?
|
Intercellular Adhesion Molecule-1 | 2 | 2000 | 1125 | 0.070 |
Why?
|
Awards and Prizes | 1 | 2010 | 360 | 0.070 |
Why?
|
src-Family Kinases | 1 | 2008 | 535 | 0.060 |
Why?
|
Vitamin E | 2 | 2000 | 871 | 0.060 |
Why?
|
Hyperglycemia | 2 | 2009 | 1371 | 0.060 |
Why?
|
Eyelids | 2 | 2022 | 278 | 0.060 |
Why?
|
Blood Circulation | 1 | 2006 | 249 | 0.060 |
Why?
|
Patient Education as Topic | 1 | 2015 | 2318 | 0.060 |
Why?
|
3-O-Methylglucose | 2 | 2019 | 37 | 0.060 |
Why?
|
Cell Adhesion | 2 | 2002 | 3088 | 0.060 |
Why?
|
Renin-Angiotensin System | 1 | 2009 | 737 | 0.060 |
Why?
|
Membrane Proteins | 3 | 2007 | 7849 | 0.060 |
Why?
|
Promoter Regions, Genetic | 3 | 2008 | 5778 | 0.060 |
Why?
|
Protease Inhibitors | 1 | 1988 | 753 | 0.060 |
Why?
|
Retinal Perforations | 1 | 2006 | 138 | 0.060 |
Why?
|
Iritis | 3 | 2004 | 15 | 0.060 |
Why?
|
Dipeptides | 1 | 1986 | 391 | 0.060 |
Why?
|
Adipose Tissue | 2 | 2006 | 3306 | 0.060 |
Why?
|
Sequence Homology, Nucleic Acid | 4 | 1995 | 1058 | 0.060 |
Why?
|
Hypertension | 2 | 2001 | 8527 | 0.060 |
Why?
|
Transcription Factors | 3 | 2004 | 12121 | 0.060 |
Why?
|
Vitreoretinopathy, Proliferative | 1 | 2004 | 76 | 0.060 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2009 | 1337 | 0.060 |
Why?
|
Angiogenic Proteins | 1 | 2004 | 101 | 0.060 |
Why?
|
Mice | 15 | 2016 | 81402 | 0.060 |
Why?
|
Sp3 Transcription Factor | 2 | 2004 | 27 | 0.050 |
Why?
|
Lasers | 4 | 1976 | 951 | 0.050 |
Why?
|
Cyclic AMP | 2 | 1998 | 1461 | 0.050 |
Why?
|
Fluoresceins | 3 | 2023 | 235 | 0.050 |
Why?
|
Sickness Impact Profile | 2 | 2016 | 299 | 0.050 |
Why?
|
Leukostasis | 2 | 2000 | 23 | 0.050 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 2 | 2007 | 472 | 0.050 |
Why?
|
Insulin-Secreting Cells | 1 | 2010 | 898 | 0.050 |
Why?
|
Medical Records | 1 | 2008 | 1407 | 0.050 |
Why?
|
Endopeptidases | 1 | 1986 | 772 | 0.050 |
Why?
|
Program Evaluation | 2 | 2005 | 2493 | 0.050 |
Why?
|
Oligonucleotides | 1 | 2005 | 582 | 0.050 |
Why?
|
Transcription, Genetic | 4 | 2002 | 7597 | 0.050 |
Why?
|
Orbit | 2 | 2011 | 457 | 0.050 |
Why?
|
Fas Ligand Protein | 1 | 2002 | 215 | 0.050 |
Why?
|
Islets of Langerhans | 2 | 1998 | 1346 | 0.050 |
Why?
|
Edema | 1 | 2006 | 769 | 0.050 |
Why?
|
Blood Flow Velocity | 1 | 2006 | 1370 | 0.050 |
Why?
|
Mice, Inbred C57BL | 8 | 2019 | 22121 | 0.050 |
Why?
|
Longitudinal Studies | 3 | 2022 | 14565 | 0.050 |
Why?
|
Molecular Sequence Data | 7 | 1998 | 17639 | 0.050 |
Why?
|
Information Services | 1 | 2003 | 236 | 0.050 |
Why?
|
Color | 1 | 2023 | 299 | 0.050 |
Why?
|
Risk Reduction Behavior | 1 | 2008 | 1112 | 0.050 |
Why?
|
Models, Economic | 1 | 2005 | 716 | 0.050 |
Why?
|
Tenon Capsule | 1 | 2011 | 3 | 0.050 |
Why?
|
Receptors, Platelet-Derived Growth Factor | 1 | 2001 | 178 | 0.050 |
Why?
|
Endothelial Cells | 4 | 2019 | 3541 | 0.050 |
Why?
|
Recombinant Proteins | 5 | 2019 | 6525 | 0.050 |
Why?
|
Lisinopril | 1 | 2001 | 61 | 0.050 |
Why?
|
Rats, Inbred WKY | 1 | 2001 | 151 | 0.050 |
Why?
|
Rats, Inbred SHR | 1 | 2001 | 186 | 0.050 |
Why?
|
Iris | 3 | 1992 | 232 | 0.050 |
Why?
|
Contrast Sensitivity | 1 | 2002 | 244 | 0.050 |
Why?
|
Laser Therapy | 5 | 1994 | 1092 | 0.040 |
Why?
|
Receptors, Leukocyte-Adhesion | 1 | 2000 | 52 | 0.040 |
Why?
|
Captopril | 1 | 2001 | 265 | 0.040 |
Why?
|
Serpins | 1 | 2002 | 247 | 0.040 |
Why?
|
Models, Immunological | 1 | 2002 | 512 | 0.040 |
Why?
|
von Willebrand Factor | 2 | 2001 | 673 | 0.040 |
Why?
|
Singapore | 1 | 2000 | 291 | 0.040 |
Why?
|
Adrenal Cortex Hormones | 1 | 2009 | 1874 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-akt | 3 | 2007 | 2453 | 0.040 |
Why?
|
Algorithms | 3 | 2016 | 14002 | 0.040 |
Why?
|
Cell Count | 2 | 2002 | 1834 | 0.040 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 3 | 2008 | 1745 | 0.040 |
Why?
|
Canthaxanthin | 1 | 1999 | 3 | 0.040 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2004 | 856 | 0.040 |
Why?
|
RNA Stability | 1 | 2001 | 331 | 0.040 |
Why?
|
Pyrazoles | 1 | 2010 | 2007 | 0.040 |
Why?
|
Fishes | 2 | 1992 | 602 | 0.040 |
Why?
|
Nerve Growth Factors | 1 | 2002 | 562 | 0.040 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2021 | 628 | 0.040 |
Why?
|
Bucladesine | 1 | 1998 | 118 | 0.040 |
Why?
|
Acids | 1 | 2019 | 125 | 0.040 |
Why?
|
Phosphotyrosine | 2 | 1996 | 455 | 0.040 |
Why?
|
Coculture Techniques | 1 | 2002 | 1340 | 0.040 |
Why?
|
Medical Records Systems, Computerized | 1 | 2005 | 1191 | 0.040 |
Why?
|
Circadian Rhythm | 2 | 2008 | 2572 | 0.040 |
Why?
|
Thionucleotides | 1 | 1998 | 112 | 0.040 |
Why?
|
Neutrophils | 2 | 2002 | 3764 | 0.040 |
Why?
|
United States | 12 | 2021 | 72202 | 0.040 |
Why?
|
Protective Agents | 1 | 2019 | 150 | 0.040 |
Why?
|
Retinoblastoma Protein | 1 | 2002 | 671 | 0.040 |
Why?
|
Plasminogen Activator Inhibitor 1 | 2 | 1999 | 277 | 0.040 |
Why?
|
Glucose Transporter Type 1 | 1 | 1998 | 186 | 0.040 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2007 | 4567 | 0.040 |
Why?
|
Proteome | 1 | 2008 | 1861 | 0.040 |
Why?
|
Immediate-Early Proteins | 1 | 2000 | 449 | 0.040 |
Why?
|
Genes | 2 | 1995 | 1844 | 0.040 |
Why?
|
DNA, Complementary | 3 | 1995 | 1992 | 0.040 |
Why?
|
Receptors, Mitogen | 1 | 1997 | 61 | 0.040 |
Why?
|
Photoreceptor Cells, Vertebrate | 1 | 2019 | 203 | 0.040 |
Why?
|
Rats, Inbred Lew | 1 | 2019 | 1155 | 0.040 |
Why?
|
Boston | 1 | 2010 | 9326 | 0.040 |
Why?
|
Guideline Adherence | 2 | 2005 | 2215 | 0.040 |
Why?
|
Hyperoxia | 2 | 1996 | 258 | 0.040 |
Why?
|
Cell Death | 1 | 2002 | 1664 | 0.040 |
Why?
|
Leukocytes | 2 | 2002 | 2024 | 0.040 |
Why?
|
Canada | 1 | 2022 | 2119 | 0.040 |
Why?
|
Purinergic P1 Receptor Antagonists | 1 | 1996 | 45 | 0.030 |
Why?
|
Optics and Photonics | 1 | 2018 | 306 | 0.030 |
Why?
|
Isoquinolines | 1 | 1998 | 351 | 0.030 |
Why?
|
Protein Isoforms | 1 | 2001 | 1697 | 0.030 |
Why?
|
Acridine Orange | 3 | 2000 | 28 | 0.030 |
Why?
|
ras Proteins | 1 | 2001 | 1052 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2000 | 570 | 0.030 |
Why?
|
Vision, Ocular | 1 | 1999 | 454 | 0.030 |
Why?
|
Myocardium | 2 | 2002 | 4700 | 0.030 |
Why?
|
Ophthalmic Solutions | 1 | 2007 | 312 | 0.030 |
Why?
|
Biomedical Research | 1 | 2011 | 3421 | 0.030 |
Why?
|
Angiography | 2 | 2021 | 1599 | 0.030 |
Why?
|
DNA Primers | 1 | 2000 | 2820 | 0.030 |
Why?
|
Blood | 1 | 1998 | 584 | 0.030 |
Why?
|
Biphenyl Compounds | 1 | 2001 | 1003 | 0.030 |
Why?
|
Weight Gain | 1 | 2006 | 2346 | 0.030 |
Why?
|
Electrooculography | 1 | 1995 | 113 | 0.030 |
Why?
|
Benzimidazoles | 1 | 2001 | 855 | 0.030 |
Why?
|
Visual Fields | 1 | 2002 | 1055 | 0.030 |
Why?
|
Oligonucleotides, Antisense | 1 | 1998 | 461 | 0.030 |
Why?
|
Collagen | 3 | 2013 | 2637 | 0.030 |
Why?
|
Insulin Resistance | 2 | 2016 | 3956 | 0.030 |
Why?
|
Plasminogen Activator Inhibitor 2 | 1 | 1995 | 19 | 0.030 |
Why?
|
Diabetic Neuropathies | 2 | 1998 | 405 | 0.030 |
Why?
|
Risk Assessment | 2 | 2015 | 23953 | 0.030 |
Why?
|
Fluoroquinolones | 1 | 2007 | 308 | 0.030 |
Why?
|
Reperfusion Injury | 1 | 2002 | 1023 | 0.030 |
Why?
|
Glycolysis | 1 | 2019 | 832 | 0.030 |
Why?
|
Proportional Hazards Models | 3 | 2020 | 12429 | 0.030 |
Why?
|
Rats, Long-Evans | 3 | 2000 | 382 | 0.030 |
Why?
|
Therapeutic Equivalency | 1 | 2015 | 134 | 0.030 |
Why?
|
Tetrazoles | 1 | 2001 | 907 | 0.030 |
Why?
|
Prognosis | 6 | 2009 | 29551 | 0.030 |
Why?
|
Drug Synergism | 1 | 1999 | 1755 | 0.030 |
Why?
|
Intention to Treat Analysis | 1 | 2015 | 414 | 0.030 |
Why?
|
N-Acetylglucosaminyltransferases | 1 | 1995 | 166 | 0.030 |
Why?
|
Rats, Zucker | 2 | 2006 | 131 | 0.030 |
Why?
|
Hydrodynamics | 1 | 2015 | 167 | 0.030 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 1 | 1996 | 483 | 0.030 |
Why?
|
Iron-Sulfur Proteins | 1 | 1994 | 83 | 0.030 |
Why?
|
Models, Biological | 1 | 2010 | 9462 | 0.030 |
Why?
|
Hemorrhage | 2 | 1983 | 3414 | 0.030 |
Why?
|
Biological Transport | 1 | 1998 | 2090 | 0.030 |
Why?
|
Solubility | 1 | 1995 | 1091 | 0.030 |
Why?
|
Creatinine | 1 | 1999 | 1898 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2022 | 22097 | 0.030 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2000 | 1649 | 0.030 |
Why?
|
Integrins | 1 | 1998 | 834 | 0.030 |
Why?
|
MAP Kinase Signaling System | 1 | 2000 | 1485 | 0.030 |
Why?
|
Calmodulin-Binding Proteins | 1 | 1994 | 232 | 0.030 |
Why?
|
Endothelium | 1 | 1995 | 765 | 0.030 |
Why?
|
Veins | 1 | 1997 | 767 | 0.030 |
Why?
|
Ophthalmoscopes | 1 | 2012 | 20 | 0.030 |
Why?
|
Cloning, Molecular | 3 | 2002 | 4174 | 0.030 |
Why?
|
Immunoglobulin Heavy Chains | 1 | 1995 | 649 | 0.030 |
Why?
|
Computer Simulation | 3 | 1996 | 6230 | 0.030 |
Why?
|
Extracellular Space | 1 | 1994 | 563 | 0.030 |
Why?
|
Autonomic Nervous System Diseases | 1 | 1995 | 269 | 0.030 |
Why?
|
Morbidity | 1 | 2018 | 1750 | 0.030 |
Why?
|
Type C Phospholipases | 2 | 2007 | 287 | 0.030 |
Why?
|
Transforming Growth Factor beta | 1 | 2000 | 1959 | 0.030 |
Why?
|
Disease Models, Animal | 4 | 2009 | 18216 | 0.030 |
Why?
|
Liver | 1 | 1988 | 7531 | 0.030 |
Why?
|
Recovery of Function | 1 | 2002 | 2975 | 0.020 |
Why?
|
Angiotensin II | 1 | 1995 | 848 | 0.020 |
Why?
|
Amino Acid Sequence | 3 | 1995 | 13445 | 0.020 |
Why?
|
Chromatography, Liquid | 1 | 2015 | 983 | 0.020 |
Why?
|
Tandem Mass Spectrometry | 2 | 2008 | 1183 | 0.020 |
Why?
|
Artifacts | 1 | 2020 | 1898 | 0.020 |
Why?
|
Mass Spectrometry | 2 | 2010 | 2189 | 0.020 |
Why?
|
Congresses as Topic | 1 | 2016 | 802 | 0.020 |
Why?
|
Area Under Curve | 1 | 2015 | 1633 | 0.020 |
Why?
|
Anastomosis, Surgical | 1 | 1995 | 983 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2023 | 1847 | 0.020 |
Why?
|
Numismatics | 1 | 2010 | 16 | 0.020 |
Why?
|
Diagnostic Errors | 1 | 2008 | 1264 | 0.020 |
Why?
|
Tissue Adhesives | 1 | 1992 | 173 | 0.020 |
Why?
|
Leisure Activities | 1 | 1992 | 308 | 0.020 |
Why?
|
Retinal Ganglion Cells | 1 | 2016 | 810 | 0.020 |
Why?
|
Lysophospholipids | 1 | 2013 | 337 | 0.020 |
Why?
|
Fibronectins | 1 | 1994 | 723 | 0.020 |
Why?
|
Mice, Transgenic | 2 | 2019 | 9533 | 0.020 |
Why?
|
Microscopy, Electron | 2 | 2009 | 2560 | 0.020 |
Why?
|
Carotid Arteries | 1 | 1995 | 941 | 0.020 |
Why?
|
Safety | 2 | 2005 | 1150 | 0.020 |
Why?
|
Cell Cycle Proteins | 1 | 2002 | 3446 | 0.020 |
Why?
|
Guidelines as Topic | 2 | 1994 | 1385 | 0.020 |
Why?
|
Anti-Infective Agents | 1 | 2007 | 984 | 0.020 |
Why?
|
HLA-DQ Antigens | 1 | 2010 | 211 | 0.020 |
Why?
|
Autoantigens | 1 | 1994 | 876 | 0.020 |
Why?
|
Sequence Homology, Amino Acid | 1 | 1994 | 2749 | 0.020 |
Why?
|
Blood Vessel Prosthesis | 1 | 1995 | 954 | 0.020 |
Why?
|
Kidney Cortex | 1 | 2009 | 169 | 0.020 |
Why?
|
Basement Membrane | 1 | 2010 | 348 | 0.020 |
Why?
|
Intraoperative Complications | 2 | 2010 | 1165 | 0.020 |
Why?
|
DNA Fragmentation | 1 | 2009 | 237 | 0.020 |
Why?
|
Phosphoproteins | 1 | 1998 | 2444 | 0.020 |
Why?
|
Medicare | 4 | 1996 | 6732 | 0.020 |
Why?
|
In Situ Nick-End Labeling | 1 | 2010 | 609 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 1996 | 1722 | 0.020 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 1 | 2009 | 184 | 0.020 |
Why?
|
Postoperative Period | 2 | 2006 | 1807 | 0.020 |
Why?
|
Transforming Growth Factor beta2 | 1 | 2009 | 71 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2008 | 15867 | 0.020 |
Why?
|
C-Peptide | 1 | 2010 | 440 | 0.020 |
Why?
|
Trabeculectomy | 1 | 2010 | 174 | 0.020 |
Why?
|
alpha-Macroglobulins | 1 | 1988 | 60 | 0.020 |
Why?
|
Protein-Tyrosine Kinases | 2 | 1995 | 2423 | 0.020 |
Why?
|
Polymerase Chain Reaction | 2 | 1995 | 6086 | 0.020 |
Why?
|
Polysaccharide-Lyases | 1 | 2007 | 47 | 0.020 |
Why?
|
Feasibility Studies | 1 | 1998 | 5236 | 0.020 |
Why?
|
Complement C1 | 1 | 2007 | 32 | 0.020 |
Why?
|
Factor XIIa | 1 | 2007 | 14 | 0.020 |
Why?
|
Cytokines | 1 | 2022 | 7377 | 0.020 |
Why?
|
Fibrinogen | 2 | 2001 | 889 | 0.020 |
Why?
|
Risk | 3 | 2009 | 9605 | 0.020 |
Why?
|
Arginine | 1 | 2011 | 933 | 0.020 |
Why?
|
Glial Fibrillary Acidic Protein | 1 | 2009 | 552 | 0.020 |
Why?
|
Infant, Newborn | 3 | 2002 | 26280 | 0.020 |
Why?
|
Glaucoma, Open-Angle | 1 | 2014 | 737 | 0.020 |
Why?
|
Platelet-Derived Growth Factor | 1 | 2009 | 618 | 0.020 |
Why?
|
Proteins | 1 | 2002 | 6033 | 0.020 |
Why?
|
Methylglucosides | 1 | 1986 | 35 | 0.020 |
Why?
|
Withholding Treatment | 1 | 2011 | 617 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-sis | 1 | 2007 | 255 | 0.020 |
Why?
|
Extravasation of Diagnostic and Therapeutic Materials | 1 | 2007 | 101 | 0.020 |
Why?
|
Acetazolamide | 1 | 2007 | 96 | 0.020 |
Why?
|
Mice, Knockout | 3 | 2009 | 14397 | 0.020 |
Why?
|
Lysine | 1 | 2011 | 992 | 0.020 |
Why?
|
Nucleic Acid Hybridization | 1 | 1988 | 1306 | 0.020 |
Why?
|
Luciferases | 1 | 2008 | 714 | 0.020 |
Why?
|
Dietary Supplements | 1 | 1999 | 3405 | 0.020 |
Why?
|
Microsomes | 1 | 1986 | 251 | 0.020 |
Why?
|
DNA | 4 | 2004 | 7208 | 0.020 |
Why?
|
Clinical Protocols | 1 | 2011 | 1438 | 0.020 |
Why?
|
Aspirin | 3 | 2004 | 3134 | 0.020 |
Why?
|
Immunohistochemistry | 2 | 2015 | 11070 | 0.020 |
Why?
|
Child | 6 | 2015 | 80086 | 0.020 |
Why?
|
Population Surveillance | 1 | 1996 | 2603 | 0.020 |
Why?
|
Pedigree | 1 | 1993 | 4586 | 0.020 |
Why?
|
Health Care Reform | 1 | 1994 | 1245 | 0.020 |
Why?
|
Refractive Errors | 1 | 1986 | 147 | 0.020 |
Why?
|
Reactive Oxygen Species | 1 | 2013 | 2137 | 0.020 |
Why?
|
Eye Hemorrhage | 1 | 2004 | 19 | 0.020 |
Why?
|
Cornea | 1 | 1992 | 1331 | 0.010 |
Why?
|
Postoperative Care | 1 | 2011 | 1471 | 0.010 |
Why?
|
Metalloendopeptidases | 1 | 1986 | 393 | 0.010 |
Why?
|
Pregnancy | 3 | 2015 | 29831 | 0.010 |
Why?
|
Immunoblotting | 1 | 2007 | 1647 | 0.010 |
Why?
|
Prevalence | 2 | 2004 | 15698 | 0.010 |
Why?
|
Aptamers, Nucleotide | 1 | 2005 | 165 | 0.010 |
Why?
|
Genes, Reporter | 1 | 2008 | 1528 | 0.010 |
Why?
|
Cross-Over Studies | 2 | 2000 | 2073 | 0.010 |
Why?
|
Extracellular Matrix Proteins | 1 | 2008 | 828 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 1995 | 4549 | 0.010 |
Why?
|
Infant, Premature | 1 | 1993 | 2104 | 0.010 |
Why?
|
Plasma | 1 | 2006 | 585 | 0.010 |
Why?
|
Age Factors | 4 | 2011 | 18379 | 0.010 |
Why?
|
Aorta | 3 | 1995 | 2042 | 0.010 |
Why?
|
Medical Record Linkage | 1 | 2004 | 285 | 0.010 |
Why?
|
Receptor, Insulin | 1 | 2006 | 832 | 0.010 |
Why?
|
Substrate Specificity | 1 | 1986 | 1792 | 0.010 |
Why?
|
Tissue and Organ Procurement | 1 | 2010 | 950 | 0.010 |
Why?
|
Phenotype | 3 | 2010 | 16585 | 0.010 |
Why?
|
Athletic Injuries | 1 | 1992 | 1213 | 0.010 |
Why?
|
Analysis of Variance | 3 | 1999 | 6230 | 0.010 |
Why?
|
Anthropometry | 1 | 2006 | 1349 | 0.010 |
Why?
|
Organizational Objectives | 1 | 2004 | 426 | 0.010 |
Why?
|
Haplotypes | 1 | 2008 | 2773 | 0.010 |
Why?
|
Actins | 1 | 2009 | 2049 | 0.010 |
Why?
|
Methods | 2 | 1980 | 1074 | 0.010 |
Why?
|
Injections, Intraperitoneal | 1 | 2002 | 412 | 0.010 |
Why?
|
E2F Transcription Factors | 1 | 2002 | 269 | 0.010 |
Why?
|
Astrocytes | 1 | 2009 | 1345 | 0.010 |
Why?
|
Dogs | 2 | 1997 | 3839 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2007 | 2852 | 0.010 |
Why?
|
Terminology as Topic | 1 | 2008 | 1534 | 0.010 |
Why?
|
Quality Control | 1 | 2004 | 826 | 0.010 |
Why?
|
NF-kappa B | 1 | 2009 | 2485 | 0.010 |
Why?
|
Spectrometry, Mass, Electrospray Ionization | 1 | 2002 | 266 | 0.010 |
Why?
|
Tumor Cells, Cultured | 2 | 1998 | 6128 | 0.010 |
Why?
|
Connective Tissue Growth Factor | 1 | 2000 | 92 | 0.010 |
Why?
|
Uveitis | 1 | 2004 | 395 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 2003 | 1627 | 0.010 |
Why?
|
Collateral Circulation | 1 | 2002 | 292 | 0.010 |
Why?
|
Uveal Diseases | 1 | 1980 | 45 | 0.010 |
Why?
|
Cycloheximide | 1 | 2000 | 343 | 0.010 |
Why?
|
Reference Values | 1 | 2008 | 4921 | 0.010 |
Why?
|
Health Facilities | 1 | 2005 | 580 | 0.010 |
Why?
|
Peptide Fragments | 2 | 2004 | 5105 | 0.010 |
Why?
|
Monte Carlo Method | 1 | 2005 | 1257 | 0.010 |
Why?
|
Oxidation-Reduction | 1 | 1986 | 2227 | 0.010 |
Why?
|
United States Department of Veterans Affairs | 1 | 2005 | 923 | 0.010 |
Why?
|
Protein Processing, Post-Translational | 1 | 2008 | 1974 | 0.010 |
Why?
|
Vitreous Detachment | 1 | 1999 | 22 | 0.010 |
Why?
|
Antibodies, Blocking | 1 | 2000 | 243 | 0.010 |
Why?
|
Kidney Glomerulus | 1 | 2002 | 567 | 0.010 |
Why?
|
Neutrophil Activation | 1 | 2000 | 180 | 0.010 |
Why?
|
Macrophage-1 Antigen | 1 | 2000 | 286 | 0.010 |
Why?
|
Metabolic Clearance Rate | 1 | 1999 | 361 | 0.010 |
Why?
|
Chronic Disease | 1 | 2014 | 9309 | 0.010 |
Why?
|
RNA | 2 | 2000 | 2721 | 0.010 |
Why?
|
Genes, jun | 1 | 1998 | 69 | 0.010 |
Why?
|
Lymphocyte Function-Associated Antigen-1 | 1 | 2000 | 377 | 0.010 |
Why?
|
Data Interpretation, Statistical | 1 | 2008 | 2691 | 0.010 |
Why?
|
Genes, fos | 1 | 1998 | 175 | 0.010 |
Why?
|
Mitogens | 1 | 1998 | 230 | 0.010 |
Why?
|
Wisconsin | 1 | 1998 | 122 | 0.010 |
Why?
|
Insulinoma | 1 | 1998 | 121 | 0.010 |
Why?
|
Preoperative Care | 1 | 2006 | 2242 | 0.010 |
Why?
|
Program Development | 1 | 2004 | 1297 | 0.010 |
Why?
|
Cell Line, Transformed | 1 | 1998 | 868 | 0.010 |
Why?
|
Laminin | 1 | 1998 | 407 | 0.010 |
Why?
|
Albuminuria | 1 | 2001 | 650 | 0.010 |
Why?
|
Retroelements | 1 | 1998 | 163 | 0.010 |
Why?
|
DNA, Antisense | 1 | 1996 | 44 | 0.010 |
Why?
|
Ligands | 1 | 2004 | 3270 | 0.010 |
Why?
|
Placenta | 1 | 1986 | 1704 | 0.010 |
Why?
|
Alleles | 1 | 2008 | 6908 | 0.010 |
Why?
|
Erythrocytes | 1 | 1986 | 2417 | 0.010 |
Why?
|
Down-Regulation | 1 | 2004 | 2911 | 0.010 |
Why?
|
Monitoring, Physiologic | 1 | 2004 | 1780 | 0.010 |
Why?
|
Cell Membrane | 1 | 1986 | 3685 | 0.010 |
Why?
|
Placebos | 1 | 2001 | 1661 | 0.010 |
Why?
|
Inositol Phosphates | 1 | 1996 | 176 | 0.010 |
Why?
|
Phospholipase C gamma | 1 | 1996 | 130 | 0.010 |
Why?
|
Hematocrit | 1 | 1998 | 625 | 0.010 |
Why?
|
Diglycerides | 1 | 1996 | 177 | 0.010 |
Why?
|
Insulin Receptor Substrate Proteins | 1 | 1998 | 553 | 0.010 |
Why?
|
Pharmaceutical Preparations | 1 | 2004 | 1087 | 0.010 |
Why?
|
Computational Biology | 1 | 2008 | 3510 | 0.010 |
Why?
|
Coronary Circulation | 1 | 2002 | 1565 | 0.010 |
Why?
|
Glucose Clamp Technique | 1 | 1996 | 263 | 0.010 |
Why?
|
Infant | 1 | 1998 | 36183 | 0.010 |
Why?
|
Saralasin | 1 | 1995 | 34 | 0.010 |
Why?
|
Proteoglycans | 1 | 1998 | 803 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2002 | 36362 | 0.010 |
Why?
|
Plasminogen | 1 | 1995 | 146 | 0.010 |
Why?
|
Outpatients | 1 | 2003 | 1596 | 0.010 |
Why?
|
Haplorhini | 1 | 1975 | 529 | 0.010 |
Why?
|
Receptors, Angiotensin | 1 | 1995 | 141 | 0.010 |
Why?
|
Serum Albumin | 1 | 1998 | 675 | 0.010 |
Why?
|
Medicine | 1 | 2003 | 941 | 0.010 |
Why?
|
Corneal Diseases | 1 | 1980 | 541 | 0.010 |
Why?
|
Fluorescent Antibody Technique | 1 | 1998 | 2468 | 0.010 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 1 | 1996 | 436 | 0.010 |
Why?
|
Quality of Life | 1 | 2016 | 13338 | 0.010 |
Why?
|
alpha 1-Antitrypsin | 1 | 1995 | 170 | 0.010 |
Why?
|
DNA Probes | 1 | 1995 | 544 | 0.010 |
Why?
|
Cell Line | 1 | 2008 | 15598 | 0.010 |
Why?
|
Polytetrafluoroethylene | 1 | 1995 | 246 | 0.010 |
Why?
|
Hospitalization | 1 | 1993 | 10698 | 0.010 |
Why?
|
Femoral Artery | 1 | 1997 | 827 | 0.010 |
Why?
|
Creatine Kinase | 1 | 1995 | 686 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2005 | 3457 | 0.010 |
Why?
|
Genetic Variation | 1 | 1988 | 6570 | 0.010 |
Why?
|
Kidney | 1 | 2008 | 7046 | 0.010 |
Why?
|
Glycosylation | 1 | 1995 | 1097 | 0.010 |
Why?
|
Retinoblastoma | 1 | 1995 | 317 | 0.010 |
Why?
|
Aorta, Abdominal | 1 | 1995 | 625 | 0.010 |
Why?
|
Obesity | 2 | 2006 | 12918 | 0.010 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2004 | 2750 | 0.010 |
Why?
|
Hyperplasia | 1 | 1995 | 1153 | 0.010 |
Why?
|
Mice, Inbred NOD | 1 | 1995 | 1824 | 0.010 |
Why?
|
Regression Analysis | 1 | 2000 | 6340 | 0.010 |
Why?
|
Decision Support Techniques | 1 | 2001 | 1998 | 0.010 |
Why?
|
Biocompatible Materials | 1 | 1998 | 1689 | 0.010 |
Why?
|
Microcirculation | 1 | 1995 | 1269 | 0.010 |
Why?
|
Triglycerides | 1 | 1998 | 2458 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2000 | 5865 | 0.010 |
Why?
|
Macaca mulatta | 1 | 1975 | 2322 | 0.010 |
Why?
|
Exudates and Transudates | 1 | 1989 | 174 | 0.000 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2000 | 4355 | 0.000 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 1995 | 1031 | 0.000 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 1998 | 2870 | 0.000 |
Why?
|
Diagnosis, Differential | 1 | 2003 | 12969 | 0.000 |
Why?
|
Interferon-gamma | 1 | 1995 | 3157 | 0.000 |
Why?
|
Genetic Predisposition to Disease | 1 | 2008 | 17854 | 0.000 |
Why?
|
Glycosuria | 1 | 1985 | 44 | 0.000 |
Why?
|
Ultrasonography | 1 | 1999 | 5966 | 0.000 |
Why?
|
Smoking | 1 | 2001 | 9046 | 0.000 |
Why?
|
Heart Rate | 1 | 1995 | 4190 | 0.000 |
Why?
|
Brain | 1 | 2009 | 27060 | 0.000 |
Why?
|
Histocompatibility Antigens Class II | 1 | 1985 | 1445 | 0.000 |
Why?
|
Cell Differentiation | 1 | 1998 | 11526 | 0.000 |
Why?
|
Pancreatic Neoplasms | 1 | 1998 | 5359 | 0.000 |
Why?
|
Postoperative Complications | 2 | 1980 | 15627 | 0.000 |
Why?
|
Medicaid | 1 | 1991 | 2810 | 0.000 |
Why?
|
Sex Factors | 1 | 1971 | 10538 | 0.000 |
Why?
|
Motivation | 1 | 1985 | 2006 | 0.000 |
Why?
|
Tolbutamide | 1 | 1969 | 23 | 0.000 |
Why?
|
Diet Therapy | 1 | 1969 | 150 | 0.000 |
Why?
|
Cerebrovascular Disorders | 1 | 1969 | 1475 | 0.000 |
Why?
|